Lee Kevin 4

What Happened
Kevin Lee, CEO of Bicycle Therapeutics (BCYC), disposed of a total of 7,683 shares in two open-market sales to satisfy tax withholding on vested RSUs. On 2026-04-02 he sold 5,967 shares at a weighted average price of $4.91 for proceeds of $29,298 (prices ranged $4.88–$4.98). On 2026-04-06 he sold 1,716 shares at a weighted average price of $5.05 for proceeds of $8,666 (prices ranged $5.03–$5.05). Combined proceeds were approximately $37,964. These sales were "sell-to-cover" transactions required by the award agreement and are not presented as discretionary sales.

Key Details

• Transaction dates and prices:
  • 2026-04-02: 5,967 shares sold, weighted avg $4.91 (range $4.88–$4.98) — $29,298
  • 2026-04-06: 1,716 shares sold, weighted avg $5.05 (range $5.03–$5.05) — $8,666
• Total shares sold: 7,683; total gross proceeds: ~$37,964.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Sales were mandated "sell to cover" to satisfy statutory tax withholding on RSU vesting (not discretionary).
  • F2/F3: Reported prices are weighted averages; multiple trade prices within the ranges above.
• Filing: Form 4 filed 2026-04-06 reporting the above transactions. The filing does not indicate a late report.

Context
"Sell-to-cover" transactions are common when restricted stock units vest and employers or award agreements require taxes be paid by selling a portion of shares; such sales are administrative and do not necessarily signal the insider's view on the company's prospects.